Abastract
Congenital anomalies (CA) are the most encountered cause of fetal death, infant mortality and morbidity.7.9 million infants are born with CA yearly. Early detection of CA facilitates life-saving treatments and stops the progression of disabilities. CA can be diagnosed prenatally through Morphology Scan (MS). Discrepancies between pre and postnatal diagnosis of CA reach 29%. A correct interpretation of MS allows a detailed discussion regarding the prognosis with parents. The central feature of PARADISE is the development of a specialized intelligent system that embeds a committee of Deep Learning and Statistical Learning methods, which work together in a competitive/collaborative way to increase the performance of MS examinations by signaling CA. Using preclinical testing and clinical validation, the main goal will be the direct implementation into clinical practice. This multi-disciplinary project offers a unique integration of approaches, competences, breakthroughs in key applications in human, psychological, technological, and economical interest such as the ‘smarter’ healthcare system, opening new fields of research. PARADISE creates an environment that contributes significantly to the healthcare system, medical and pharma industries, scientific community, economy and ultimately to each individual. Its outcome will increase impact on the management of CA by enabling the establishment of detailed plans before birth, which will decrease morbidity and mortality in infants.